Diagnostic performance of the 2024 LI-RADS nonradiation treatment response algorithm in hepatocellular carcinoma treated with locoregional plus immune-targeted therapy
European Journal of Radiology · 2026
DOI: 10.1016/j.ejrad.2026.113111 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Radiology, 2026. Verfasst von Hongli Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Algorithms, Magnetic Resonance Imaging. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) nonradiation Treatment Response Assessment (TRA) version 2024 (v2024) in assessing treatment response of hepatocellular carcinoma (HCC) following downstaging locoregional therapy (LRT) plus immune-targeted therapy; to compare its diagnostic performance with LI-RADS TRA version 2018 (v2018); and to explore the added diagnostic value of its ancillary features (AFs). METHODS: This retrospective study included patients with HCC who underwent LRT plus immune-targeted therapy followed by hepatectomy between January 2021 and December 2025. Two radiologists independently assigned LR-TR classifications to lesions on MRI according to the LI-RADS Nonradiation TRA v2024 and v2018. With pathological findings from hepatectomy as the reference standard, the sensitivity, specificity and accuracy of the two versions were calculated. Diagnostic performance for identifying residual tumor viability was compared using the McNemar test. RESULTS: A total of 132 patients (19 women, 113 men; mean age, 55.9 ± 9.5 years [standard deviation]) with 143 treated HCC lesions were enrolled in this study. The LR-TR Viable category of v2024 yielded a sensitivity of 66.3% (95% confidence interval [CI]: 57.1%-75.5%) and a specificity of 95.2% (95% CI: 84.2%-98.7%) for predicting pathologic viability. For identifying complete pathologic necrosis, the LR-TR Nonviable category showed a sensitivity of 76.2% (95% CI: 63.3%-89.1%) and a specificity of 95.1% (95% CI: 90.8%-99.3%). The incorporation of AFs significantly improved the sensitivity for detecting pathologic viability (87.1% vs. 66.3%, P < 0.001), with no significant difference in specificity (90.5% vs. 95.2%, P = 0.500). Overall, LI-RADS nonradiation TRA v2024 integrated with AFs exhibited superior diagnostic performance relative to LI-RADS TRA v2018. CONCLUSION: The LI-RADS nonradiation TRA v2024 incorporating AFs showed excellent diagnostic performance and outperformed LI-RADS TRA v2018 for assessing tumor viability in HCC patients treated with LRT plus immune-targeted therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
- Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China. Electronic address: chenxj202311@163.com.
Zitieren
APA
Yang, H., Zhang, Z., Han, S., Xiang, Y., Zheng, X., & Chen, X. (2026). Diagnostic performance of the 2024 LI-RADS nonradiation treatment response algorithm in hepatocellular carcinoma treated with locoregional plus immune-targeted therapy. European Journal of Radiology. https://doi.org/10.1016/j.ejrad.2026.113111
Vancouver
Yang H, Zhang Z, Han S, Xiang Y, Zheng X, Chen X. Diagnostic performance of the 2024 LI-RADS nonradiation treatment response algorithm in hepatocellular carcinoma treated with locoregional plus immune-targeted therapy. European Journal of Radiology. 2026. doi:10.1016/j.ejrad.2026.113111
BibTeX
@article{Yang2026,
author = {Yang, Hongli and Zhang, Zhenzhen and Han, Shuai and Xiang, Yue and Zheng, Xin and Chen, Xuejun},
title = {Diagnostic performance of the 2024 LI-RADS nonradiation treatment response algorithm in hepatocellular carcinoma treated with locoregional plus immune-targeted therapy},
journal = {European Journal of Radiology},
year = {2026},
doi = {10.1016/j.ejrad.2026.113111}
}
EUVIMED